Although the clearance of RAS mutations is a rare event (7), it is conceivable that subclones with RAS mutations are less fit in the untreated tumor and acquire fitness as a consequence of adaptation to the microenvironment induced by EGFR therapies. Here, EGFR is linked to neoplasm.